DAVID GRANOVSKY

Archive for April 20th, 2009|Daily archive page

Adult Stem Cells Help Stroke Victims

In ALL ARTICLES, VICTORIES & SUCCESS STORIES on April 20, 2009 at 10:48 pm

brain-stroke-21

Stem Cell Research Shows Adult Stem Cells Help Stroke Victims

Posted 20 April, 2009 in Stroke |

Stem Cell Research Study Reveals Stroke Patients Helped by Own Stem Cells

A new stem cell research study/trial recently completed shows that implanting a person’s own Adult Stem Cells helps stroke patients overcome partial paralysis. Dr. Kameshwar Prasad of the All India Institute of Medical Sciences (AIIMS) will present his stem cell study at the European Stroke Research Conference in May, 2009.

Stroke Victims Own Adult Stem Cells Used

In the stem cell study that took place in New Delhi, India, 12 stroke victims had their own stem cells implanted within 1 month after a stroke. Also, 3 stroke patients were used as a control group and were not given any stem cells.

Process of Stem Cells for Stroke

  1. Adult Stem Cells extracted from patient’s bone marrow
  2. Stem Cells are then purified
  3. Patient’s own stem cells are then reintroduced intravenously into the antecubital vein (in the forearms, near the elbow)
  4. Stem Cells migrate to area of injury (in this case- the brain)
  5. Adult Stem Cells enhance repair process and reduce brain damage

The Stem Cell Treatment Results

At the beginning of the stem cell study, none of the 12 stroke patients were able to carry out daily activities, use the toilet, take a bath, dress and eat independently.

However, within 1 year, 70% (I assume 7 or 8 of the patients) were able to overcome their handicaps and successfully return to previous activities like playing golf, working in the office and cooking.

Only 1 out of the 3 stroke patients in the control group were able to go back to their normal routine.

No Side Effects From Your Own Stem Cells

From the stem cell article:
“The stem cells had excellent safety profile. After carrying out Pet scans and MRIs thrice in a year on patients who received stem cells, we found no side-effects. This study shows that stem cells are a safe and feasible therapy in acute stroke. This holds promise and needs to be confirmed in a bigger study,” Dr Prasad said.

Of course there were no side effects, the trial used the patient’s own cells. Rejection isn’t an issue.  As I say time and time again, the patient has everything to gain and nothing to lose.  There is no downside to this treatment.  It is a shame this isn’t being put to use in the United States and made available to everyone who may need it.

These same doctors will follow up this stem cell clinical trial for stroke with a 120 patient trial in the next 3 years.  Hopefully, this will speed things up for Adult Stem Cells to be accepted sooner rather than later.

Related Stem Cells for Stroke Success Stories

The results of this study comes just after I covered this stem cell trial for stroke in Texas.  Also, earlier this year, I covered the stem cell tea bag which helped a German stroke victim as well.

see also:

Brain Reconstruction: Stem-Cell Scaffolding Can Repair Stroke Damage

Stem Cells Revive Woman in Coma From Stroke

STEM CELLS & STROKE

via Stem Cell Research Shows Adult Stem Cells Help Stroke Victims | Adult Stem Cell Research.

Report: Pharma Deals In 1Q Exceed Whole Of 2008

In ALL ARTICLES, BUSINESS OF STEM CELLS on April 20, 2009 at 9:23 pm

“The report predicts mergers and acquisitions will grow in the next few quarters in the stem-cell arena, following President Obama’s executive order allowing use of federal funding for embryonic stem-cell research.

Let’s not forget that Obama gave the responsibility of establishing the US position on stem cell funding to the NIH…and they came back with limited funding for embryonic and full funding for adult stem cell and ips cell research.

https://repairstemcell.wordpress.com/2009/04/17/nih-stem-cell-guidelines-part-3-brief/

https://repairstemcell.wordpress.com/nih-draft-guidelines-for-stem-cell-research-041609/

Could this be because the know that adult stem cells have worked for over 6 years and iPS cells may have a lot of potential…whereas embryonic has huge limitations and obstacles and a decade long timeline prior to generating treatments?  – dg

Venture capitalists and large drug makers seeking to boost their stem-cell research capabilities are likely to invest in the field, according to the report.”

money-stacks1

Report: Pharma Deals In 1Q Exceed Whole Of 2008

By Linda A. Johnson, AP Business Writer

Manufacturing.Net – April 20, 2009

Printer Friendly E-mail to a Colleague

TRENTON, N.J. (AP) — The burst of drugmaker mergers announced in the first quarter is worth nearly 50 percent more than all the industry deals announced in 2008, according to a new report.

Deals in the quarter had a combined value of $166 billion, more than 10 times the value of deals announced in last year’s first quarter and well over the $114 billion in deals announced in all of 2008.

That’s according to a report released Monday by The Mergermarket Group of New York and London.

First-quarter deals include three involving the 10 largest drugmakers.

The Roche Group bought the 44 percent of Genentech Inc. it didn’t already own for $47 billion. Pfizer Inc. is buying Wyeth for $64 billion and Merck & Co. is buying Schering-Plough Corp. for $43 billion. Those deals are set to close in the fourth quarter.

According to the report, some insiders don’t see any more megadeals on the horizon and instead expect more “mid-market transactions” and deals valued below $5 billion.

One was announced Monday morning, in fact, with British drugmaker GlaxoSmithKline PLC saying it will pay $2.9 billion to buy American dermatology business Stiefel Laboratories Inc.

Glaxo and some other major drugmakers, including Sanofi-Aventis SA and Bristol-Myers Squibb Co., have been telling investors and analysts that they prefer to make smaller, targeted acquisitions that fit with their particular growth strategies.

The report predicts mergers and acquisitions will grow in the next few quarters in the stem-cell arena, following President Obama’s executive order allowing use of federal funding for embryonic stem-cell research.

Venture capitalists and large drugmakers seeking to boost their stem-cell research capabilities are likely to invest in the field, according to the report. One potential target for big drugmakers is International Stem Cells Corp., which is doing early-stage testing of treatments using stem cells.

via Report: Pharma Deals In 1Q Exceed Whole Of 2008.

%d bloggers like this: